• Who we are
    • ABOUT MEDICINES FOR EUROPE
    • PURPOSE AND OBJECTIVES
    • OUR VALUES – OUR 5 PILLARS
    • STRUCTURE
    • MEMBERS
    • BECOME A MEMBER
    • CODE OF CONDUCT
    • DISCLOSURE
    • Vacancies
  • PRIORITIES
  • Key topics
    • ACCESS
    • INDUSTRIAL POLICY
    • REGULATORY AND LEGAL FRAMEWORK
    • FALSIFIED MEDICINES
    • SUSTAINABILITY
    • ANTIMICROBIAL RESISTANCE
    • MEDICINE SHORTAGES
  • Publications
    • EXTERNAL RESOURCES
    • FACTSHEETS
    • INFOGRAPHICS
    • PODCAST
    • POLICY
    • REPORTS
    • VIDEOS
  • Newsroom
    • IN THE NEWS
    • PRESS RELEASES
  • Contact us
Login Login
Medicines for Europe
  • Generic medicines
    • Home
    • Medicines for Europe
      • Generic medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • Definition
      • THERAPEUTIC AREAS
      • GLOSSARY
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Related links
      • Contact us
    • Twitter
  • Biosimilar medicines
    • Home
    • Medicines for Europe
      • Biosimilar medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • DEFINITION
      • THERAPEUTIC AREAS
      • GLOSSARY
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
      • External resources
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Related links
      • Contact us
    • Twitter
  • Value added medicines
    • Home
    • Who we are
      • Value added medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • Definition
      • THERAPEUTIC AREAS
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Contact us
  • Events

Twenty years of the Legal Affairs Conference: Driving Europe’s competitiveness and timely access to medicines

9 June 2026

Related Posts

  • EU policies must not push essential medicines off… 9 February 2026 President Steffen Saltofte argues that EU policy must protect timely…
  • IQVIA - Assessing the Biosimilar Void 30 October 2023 While biosimilar competition in Europe has played a vital role…
  • Pharma reform should provide for more timely patient… 24 June 2025
  • ‘Access Is A Right, Not A Privilege’ – Medicines For… 9 February 2026 The president of Medicines for Europe, Steffen Saltofte, says Medicines…
Medicines for Europe
MEMBER OF
IGBA EMVO
  • Contact us
  • Privacy Policy
Medicines for Europe AISBL
Rue d’Arlon 50
1000 Brussels Belgium
T : +32 (0)2 736 84 11
Powered by Big Smile Agency
Medicines For Europe
  • Who we are
  • Vacancies
  • PRIORITIES
  • Key topics – COVID-19
  • Publications
  • Newsroom
  • Contact us
  • SECTOR GROUPS
    • Generic medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
      • FIND OUT MORE
    • Biosimilar medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
      • FIND OUT MORE
    • Value added medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
  • Events
 Share This
 LinkedIn

Share on Mastodon

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.